Pink Sheet is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


'Right To Try' Or 'Right To Ask'? Hearing Spotlights Adverse Events As Key Barrier To Expanded Access

Executive Summary

FDA and the pharmaceutical industry appear to have a shared interest in finding ways to dramatically increase expanded access programs to avoid a potentially difficult fight over 'Right to Try' legislation at the federal level in 2017. A September 22 hearing on a pending Senate bill illustrates why.


Related Content

FDA Policy Says Right-to-Try Talks Are Between Providers, Sponsors
'Right To Try' Bill Contradicts US FDA’s Mission, Former Official Says
'Right to Try' Has White House Support: Add-On To PDUFA Looks Tough To Stop
Trump Promises Changes To 'A Lot Of Rules' At US FDA
Scrutiny Of EpiPen Pricing Invited By Mylan Lobbying, Congressman Says
Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry
FDA Can't Win On Guidances: Expanded Access Policy, Duchenne Worries Collide
New US Compassionate Use Tool Would Need Support Of Drug Makers
J&J's Compassionate Use Advisory Cmte. May Become Industry Model


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts